Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of BMS-986278 in idiopathic pulmonary fibrosis
MOH_2023-10-26_013013Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF) (6 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Number of spontaneous syncope events and Absolute change from baseline in forced vital capacity. Started Sep 2023; status: recruiting.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2023-10-26_013013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-26_013013.